Convergent Therapeutics
Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. The company offers a proprietary platform that links humani...
Valuation
$280M
Latest known
Share Price
N/A
Total Raised
$130M
Last Round
N/A